BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, Hughes SG, Gaudet D, Hegele RA, O'Dea LSL, Stroes ESG, Tsimikas S, Witztum JL; COMPASS study group. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021;9:264-75. [PMID: 33798466 DOI: 10.1016/S2213-8587(21)00046-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Gouni-Berthold I, Schwarz J. New therapeutic approaches for the treatment of hypertriglyceridemia. Herz 2022. [PMID: 35451595 DOI: 10.1007/s00059-022-05113-x] [Reference Citation Analysis]
2 Goga A, Stoffel M. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nat Rev Drug Discov 2022. [PMID: 35210608 DOI: 10.1038/s41573-022-00407-5] [Reference Citation Analysis]
3 Cheng Y, Li T, Tan P, Du Y, Huang Z, Shi H, Cai T, Chen Y, Fu W. Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis. Endocrine 2022. [PMID: 35298785 DOI: 10.1007/s12020-022-03025-8] [Reference Citation Analysis]
4 Lee CK, Liao CW, Meng SW, Wu WK, Chiang JY, Wu MS. Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. Biomedicines 2021;9:985. [PMID: 34440189 DOI: 10.3390/biomedicines9080985] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, Baum SJ, Hurh E, Bartlett VJ, Kingsbury J, Figueroa AL, Alexander VJ, Tami J, Witztum JL, Geary RS, O'Dea LSL, Tsimikas S, Gaudet D. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J 2022:ehab820. [PMID: 35025993 DOI: 10.1093/eurheartj/ehab820] [Reference Citation Analysis]
6 Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol 2021. [PMID: 34625741 DOI: 10.1038/s41569-021-00613-5] [Reference Citation Analysis]
7 Xu J, Ashjian E. Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline. J Pharm Pract 2021;:8971900211053489. [PMID: 34720008 DOI: 10.1177/08971900211053489] [Reference Citation Analysis]
8 Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, Gąsior M, Jankowski P, Jóźwiak J, Kłosiewicz-Latoszek L, Kowalska I, Małecki M, Prejbisz A, Rakowski M, Rysz J, Solnica B, Sitkiewicz D, Sygitowicz G, Sypniewska G, Tomasik T, Windak A, Zozulińska-Ziółkiewicz D, Cybulska B. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021;17:1447-547. [PMID: 34900032 DOI: 10.5114/aoms/141941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bejar N, Tat TT, Kiss DL. RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases. Curr Atheroscler Rep 2022. [PMID: 35364795 DOI: 10.1007/s11883-022-01007-9] [Reference Citation Analysis]
10 Hackam DG, Hegele RA. Lipid-Modifying Therapies and Stroke Prevention. Curr Neurol Neurosci Rep 2022. [PMID: 35554824 DOI: 10.1007/s11910-022-01197-4] [Reference Citation Analysis]
11 Blom DJ, Marais AD, Moodley R, van der Merwe N, van Tonder A, Raal FJ. RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis 2022;21:41. [PMID: 35459248 DOI: 10.1186/s12944-022-01649-3] [Reference Citation Analysis]
12 Paquette M, Bernard S. The Evolving Story of Multifactorial Chylomicronemia Syndrome. Front Cardiovasc Med 2022;9:886266. [DOI: 10.3389/fcvm.2022.886266] [Reference Citation Analysis]
13 Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J 2022:ehab841. [PMID: 35051271 DOI: 10.1093/eurheartj/ehab841] [Reference Citation Analysis]
14 Ward NC, Chan DC, Watts GF. A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy? BioDrugs 2022. [PMID: 35286660 DOI: 10.1007/s40259-022-00520-2] [Reference Citation Analysis]
15 Visser J, van Zwol W, Kuivenhoven JA. Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins. Curr Atheroscler Rep 2022. [PMID: 35107764 DOI: 10.1007/s11883-022-00979-y] [Reference Citation Analysis]